3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
7
Brain Neoplasms
5
Prostatic Neoplasms
4
Oligodendroglioma
2
Neoplasms
2
Glioma
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Venous Thromboembolism
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Meningioma
1
Malignant Neoplasms of Female Genital Organs
1
Lung Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Ependymoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Gemcitabine
6
Cisplatin
6
Bortezomib
6
venetoclax
5
elotuzumab
4
isatuximab
3
blinatumomab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
ixazomib
2
dexamethasone 21-phosphate
2
cabazitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
abemaciclib
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled